Probe into risk of optic nerve disease from semaglutide

A JAMA Oncology investigation has looked into the whether prescriptions for semaglutide are associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes or patients who are overweight or obese.

The blockbuster diabetes and weight loss drug is sold by Novo Nordisk (NOV: N) under the brand names Ozempic, Rybelsus and Wegovy. 

Its use is on the increase globally as studies suggest impressive outcomes in diabetes, metabolic and cardiovascular diseases. Results in obesity, in particular, have prompted soaring demand.